J.P. Morgan Healthcare Conference Presentation
Reshaping the HIV market, ~£7bn sales in 2026
Our commitments
Pioneering innovation for treatment and
prevention
6% to 8% sales CAGR 2021-26*
• Dovato and cabotegravir drive growth via
competitive execution
.
Cabotegravir replaces dolutegravir as
foundational medicine
2026-31 LA¹ pipeline growth drivers
Targeting four-monthly dosing for LA regimens
in treatment and prevention
Roadmap to extend to six-monthly dosing by
end of decade
ULA² PrEP
Target product profiles
2026
Q4M file
and launch
2027
2028-30
Q6M file
and launch
Q4M file
and launch
File and
launch
ULA treatment
LA self-admin
treatment
Q6M file
and launch
GSK
1. Long-acting 2. Ultra-long-acting
• Multiple pathways to deliver LA treatment and
prevention
* Forecasted CAGR is based on a constant exchange rate and includes an estimated ~£200m annual impact from 2025 of the US Inflation Reduction Act which has up to a one percentage point impact on the CAGR.
Anticipated 2026 sales are based on 2023 exchange rates.
7View entire presentation